Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nerviheal OD is an oral nutraceutical softgel capsule developed by Heal All Pharmaceuticals for the management of diabetic and drug-induced neuropathy, as well as cardiovascular complications associated with high oxidative stress. It is a multi-ingredient combination containing methylcobalamin (1500 mcg), alpha-lipoic acid (100 mg), folic acid (1.5 mg), vitamin B6 (1.5 mg), chromium picolinate (500 mcg), sodium selenite (75 mcg), and zinc sulfate monohydrate (7.5 mg). Methylcobalamin (an active form of Vitamin B12) and vitamin B6 support nerve regeneration and myelin sheath formation, while alpha-lipoic acid acts as a potent antioxidant to reduce oxidative stress in nerve tissues. Folic acid, chromium, selenium, and zinc provide essential nutritional support to improve nerve conduction and metabolic function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nerviheal OD.